OptiBiotix Health Past Earnings Performance
Past criteria checks 2/6
OptiBiotix Health has been growing earnings at an average annual rate of 46.4%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 41.2% per year. OptiBiotix Health's return on equity is 27.2%, and it has net margins of 470.4%.
Key information
46.4%
Earnings growth rate
45.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 41.2% |
| Return on equity | 27.2% |
| Net Margin | 470.4% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How OptiBiotix Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 1 | 6 | 2 | 0 |
| 31 Mar 22 | 2 | 6 | 2 | 0 |
| 31 Dec 21 | 2 | 6 | 2 | 0 |
| 30 Sep 21 | 2 | 13 | 2 | 0 |
| 30 Jun 21 | 2 | 21 | 2 | 0 |
| 31 Mar 21 | 2 | 13 | 2 | 0 |
| 31 Dec 20 | 2 | 6 | 2 | 0 |
| 31 Dec 19 | 1 | -2 | 2 | 0 |
| 31 May 19 | 1 | -2 | 2 | 0 |
| 28 Feb 19 | 1 | -2 | 2 | 0 |
| 30 Nov 18 | 1 | -2 | 2 | 0 |
| 31 Aug 18 | 0 | -2 | 2 | 0 |
| 31 May 18 | 0 | -2 | 2 | 0 |
| 28 Feb 18 | 0 | 0 | 2 | 0 |
| 30 Nov 17 | 0 | 2 | 2 | 0 |
| 31 Aug 17 | 0 | 2 | 2 | 0 |
| 31 May 17 | 0 | 2 | 1 | 0 |
| 28 Feb 17 | 0 | 1 | 1 | 0 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -1 | 1 | 0 |
Quality Earnings: OPBX.F has a high level of non-cash earnings.
Growing Profit Margin: OPBX.F's current net profit margins are lower than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPBX.F's earnings have grown significantly by 46.4% per year over the past 5 years.
Accelerating Growth: OPBX.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: OPBX.F had negative earnings growth (-71.4%) over the past year, making it difficult to compare to the Biotechs industry average (-42.7%).
Return on Equity
High ROE: OPBX.F's Return on Equity (27.2%) is considered high.